QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

AMRN

QT68Amarin Corporation plc
NASDAQ·Healthcare·Biotechnology·Ireland
Latest market price
16.03
+0.26+1.65%
OverviewShort InterestFilings
AMRNQT68Amarin Corporation plc·NASDAQ
OverviewShort InterestFilings
16.03+1.65%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E-EPS (ttm)
-1.62
Insider Own5.42%
Shs Outstand414.19M
Perf Week7.58%
Market Cap326.17MForward P/E291.45EPS next Y0.06Insider Trans0.01%Shs Float-Perf Month14.09%
Enterprise Value200.69MPEG-EPS next Q-0.09Inst Own-Short Float-Perf Quarter6.87%
Income-33432153.00P/S1.52EPS this Y97.84%Inst Trans-Short Ratio-Perf Half Y14.75%
Sales214.89MP/B0.73EPS next Y257.14%ROA-5.20%Short Interest-Perf YTD14.83%
Book/sh1.08P/C12.86EPS next 5Y-ROE-7.34%52W High20.90 -23.30%Perf Year19.54%
Cash/sh0.74P/FCF12.79EPS past 3/5Y-ROIC-7.76%52W Low12.30 30.33%Perf 3Y-
Dividend Est.-EV/EBITDA-39.05Sales past 3/5Y-16.61% -19.01%Gross Margin52.48%Volatility2.96% 2.75%Perf 5Y-
Dividend TTM-EV/Sales0.93EPS Y/Y TTM97.50%Oper. Margin-17.38%ATR (14)0.62Perf 10Y-
Dividend Ex-Date-Quick Ratio2.46Sales Y/Y TTM-6.11%Profit Margin-15.64%RSI (14)68.58Recom2.94
Dividend Gr. 3/5Y-Current Ratio3.48EPS Q/Q-SMA209.01%Beta0.73Target Price2.17
Payout0.00%Debt/Eq0.01Sales Q/Q2.38%SMA509.75%Rel Volume1.12Prev Close15.77
Employees275LT Debt/Eq0.03EarningsJul 29SMA2004.18%Avg Volume78.08KPrice16.03
IPO DateApr 01, 1993Option/ShortYes / YesEPS/Sales Surpr.-1000.00% 2.27%Net Debt/EBITDA24.41Volume87,086Change1.65%
Analyst Ratings
DateActionAnalystRatingTarget
Oct-25-23DowngradeJefferiesBuy → Hold
Jan-06-23UpgradeJefferiesHold → Buy$3.00
May-24-22ReiteratedGoldman SachsSell$1.50
May-06-22DowngradeJP MorganNeutral → Underweight
May-05-22DowngradeSVB LeerinkOutperform → Market Perform
May-05-22DowngradeHC Wainwright & Co.Buy → Neutral
May-05-22ReiteratedNorthland Securities$2.00
May-12-21DowngradeGoldman SachsNeutral → Sell
Mar-31-20DowngradeJefferiesBuy → Hold
Mar-31-20UpgradeOppenheimerUnderperform → Perform
Latest News
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue215214229
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A10293147
Gross Profit11212181
Selling, General and Administrative Excl. Other100115152
Research and Development192021
Other Operating Expense3100
Operating Income-37-14-92
Interest Expense000
Unusual Expense
———
Non-Operating Income (Expense)-2922-15
Net Income Before Taxes-34-36-77
Income Taxes-135
Consolidated Net Income-34-39-82
Net Income From Continuing Operations-34-39-82
Net Income-34-39-82
EPS (Recurring)-1.62-1.80-4.00
EPS (Basic, Before Extraordinaries)-1.62-1.80-4.00
EPS (Diluted)-1.62-1.80-4.00
EBITDA-5-33-74
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio
———
Price To Sales Ratio1.571.37—
Gross Margin52.0956.5435.37
Operating Margin-17.21-6.54-40.17
Net Margin-15.81-18.22-35.81
Shares Outstanding212121
Market Capitalization337293—
Operating Lease Expense
———
Insider Trading Volume
$17.47$15.95$14.42$12.90$11.38● Close Price0.00K0.00K0.00K0.00K0.00KUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Bonfiglio Patrice EadonDirectorApr 18 '26Option Exercise0.001,67601,239Apr 22 12:00 AM
Sterling Louis IIIDirectorApr 18 '26Option Exercise0.001,67604,452Apr 21 12:00 AM
Odysseas Kostas DDirectorApr 18 '26Option Exercise0.001,67601,239Apr 21 12:00 AM
Horn KeithDirectorApr 18 '26Option Exercise0.001,67601,239Apr 21 12:00 AM
O'Connor OliverDirectorApr 18 '26Option Exercise0.001,67601,239Apr 21 12:00 AM
Sullivan Diane E.DirectorApr 18 '26Option Exercise0.001,67601,239Apr 21 12:00 AM
Cohen PaulDirectorApr 18 '26Option Exercise0.001,67601,239Apr 21 12:00 AM
Fishman Peter L.SVP, CFOApr 01 '26Option Exercise0.0025006,282Apr 02 12:00 AM
Fishman Peter L.SVP, CFOJan 31 '26Option Exercise0.004,79207,165Feb 03 12:00 AM
Berg AaronPresident and CEOJan 31 '26Option Exercise0.008,358083,658Feb 03 12:00 AM
Ketchum Steven BEVP, Chief Scientific OfficerJan 31 '26Option Exercise0.008,358041,941Feb 03 12:00 AM
Keenan David PaulEVP, Chief Operating OfficerJan 31 '26Option Exercise0.008,358012,718Feb 03 12:00 AM
Provoost JonathanEVP, Chief Legal OfficerJan 02 '26Option Exercise0.003,68803,688Jan 06 12:00 AM
Ketchum Steven BEVP, Chief Scientific OfficerJan 02 '26Option Exercise0.003,688041,038Jan 06 12:00 AM
Fishman Peter L.SVP, CFOJan 02 '26Option Exercise0.002,44706,435Jan 06 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR